BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

As Arcus becomes the second company to report clinical data for a CD73 inhibitor in pancreatic cancer behind front-runner AstraZeneca, at least six more teams have early-stage clinical programs targeting the immuno-metabolism modulating receptor. An...
BioCentury | Jan 16, 2021
Translation in Brief

Dyne’s POC myotonic dystrophy data; plus pulmonary T cell subset contributes to local antibody production after reinfection, DiosCURE’s COVID candidates and more

Dyne’s myotonic dystrophy antisense therapy reduces gene expressionDyne Therapeutics Inc. (NASDAQ:DYN) reported data from a new mouse model of severe disease showing its myotonic dystrophy type 1 (DM1) antisense oligonucleotide therapy reduced nuclear DMPK RNA levels...
BioCentury | Jan 16, 2021
Product Development

Zymeworks showcases >45% confirmed ORRs for anti-HER2 bispecific in biliary, gastroesophageal cancers

Phase I data Zymeworks presented Friday for its bispecific anti-HER2 mAb back its ongoing and pending pivotal trials in biliary tract and gastroesophageal cancers, respectively. In an oral presentation at the American Society of Clinical Oncology...
BioCentury | Jan 15, 2021
Product Development

Readout for Arcus’ pancreatic cancer program could spur Gilead to exercise option

Early data showing clinical efficacy of a combination from Arcus in pancreatic cancer increases the likelihood that Gilead will exercise its option on the biotech’s potentially first-in-class molecule targeting CD73. An interim readout from the...
BioCentury | Jan 15, 2021
Product Development

Phase I/II antibody levels support single shot for J&J COVID-19 vaccine: Data Byte

...CD4+ T cells, and 36% had spike-reactive CD8+ T...
...values were 76% and 51% for  CD4+ and CD8+ T...
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support a Phase II trial of its leading cancer vaccines in combination with...
BioCentury | Jan 13, 2021
Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

...endocytosis of the vehicle and its cargo.Four therapies for blood cancers target either CD4+ or CD8+...
BioCentury | Jan 12, 2021
Deals

bluebird’s split could yield two attractive M&A targets

bluebird’s decision to focus on rare diseases and spin out its cancer business by year-end could provide the focus both units need to execute on their pipelines and attract potential partners and buyers.  Nick Leschly,...
BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

EQRx is planning to deliver on its promise to provide equivalent or better low-cost drugs ahead of schedule with a $500 million series B, with diverse investor interest reflecting a mission that has only...
BioCentury | Jan 12, 2021
Deals

Novartis gains rights to BeiGene’s PD-1 in North America, Europe and Japan for $650M up front

After regaining worldwide rights to tislelizumab from Celgene Corp. in mid-2019, BeiGene has found a partner in major-market territories for the PD-1 inhibitor in Novartis, which paid $650 million up front on Monday for rights in...
Items per page:
1 - 10 of 12685